Latest Financial Results News

archTIS delivered a 231% year-on-year increase in annual recurring revenue to A$15.1 million, marked by the full deployment of its US Department of Defense custom software and a significant contract with a US-European military alliance.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.

DXN Limited posted a 47.5% revenue increase to $3.7 million in Q3 FY26, buoyed by a surge in modular data centre projects and a growing pipeline of 891 identified contracts. The company advanced its Asia-Pacific footprint through a JV in Indonesia and a Malaysian manufacturing push, while securing a $5.3 million Cable Landing Station contract in Latin America.

Regis Healthcare expects FY26 underlying EBITDA of approximately $135 million, buoyed by near-record occupancy and a disciplined capital strategy amid evolving government reforms.

Microba Life Sciences reported a 99% year-on-year surge in core testing revenue for Q3 FY26, propelled by strong test volume growth and new clinic contracts in Australia and the UK. The company is advancing a major product release and negotiating a significant corporate transaction to bolster its financial position.

Adveritas Limited surged to $15.08 million ARR, up 91% year-on-year, powered by a new self-serve SME platform and AI-driven product enhancements.

BSA Limited recorded a break-even Q3 FY2026 as revenue and EBITDA fell sharply year-to-date due to lost contracts, but the company maintains a solid cash buffer to fund its transition.

Appen Limited’s Q1 FY26 revenue rose 9% year-on-year to $54.8 million, driven by an 88% surge in its China business. Despite a 37% drop in the Global segment due to seasonality, the company reaffirmed full-year guidance and highlighted expanding AI operational efficiencies.

Energy Metals Limited (ASX: EME) reported a 12% increase in uranium resources at its Bigrlyi Project to 10,900 tonnes U3O8, driven by successful drilling and modelling. The company plans to advance technical studies and further exploration in 2026, supported by a solid cash position and strategic backing from China General Nuclear Power Group.

Dubber Corporation reported a historic positive underlying operating cashflow run-rate in Q3 FY26, driven by a USD 3.06 million initial payment from a Tier 1 North American communications service provider and ongoing cost reductions. Recurring revenue dipped 6% quarter-on-quarter due to portfolio optimisation and foreign exchange impacts.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.